Anatomic Pathology - CMOCO

The Colorado Molecular Correlates Laboratory (CMOCO) is a state of the art facility, located within the University Of Colorado Denver’s Department of Pathology. CMOCO is dedicated to making advancements in new pathological technologies. Under the direction of Dr. Wilbur Franklin and Dr. M. Scott Lucia, the mission of CMOCO is to provide supplemental diagnostic and prognostic tools to medical clinicians and researchers.

EGFr Testing
Helps determine whether a solid tumor, such as of the lung (non small cell), head and neck, colon, pancreas, or breast, is positive for EGFR, which helps to guide treatment and determine prognosis. For example, in patients with non-small cell lung cancer (NSCLC) treatment with EGFR tyrosine kinase inhibitors might be indicated.

Her2/ Neu Testing
Her-2/neu testing is used as a prognostic and monitoring marker to help determine how aggressive a breast cancer tumor is likely to be, and as a predictor of response to therapies such as hormone therapy and chemotherapy.

KRAS Testing
Mutations in the KRAS gene have been described in approximately 30-50% of colorectal carcinomas and approximately 15-30% of lung adenocarcinomas. Mutated KRAS in tumor tissue has been associated with non-response and no benefit from the epidermal growth factor receptor (EGFR) inhibitors cetuximab and panitumumab for Colon Cancer and erlotinib for NSCLC. KRAS testing may help physicians and their patients in making decisions regarding treatment with EGFR-related chemotherapy.

HC2 DNA HPV Testing

Veridex CTC Testing
The CellSearchTM Circulating Tumor Cell (CTC) Test from Veridex is a simple blood test that captures and assesses CTC’s to determine the prognosis of patients with metastatic breast, colorectal or prostate cancer at any time. The test offers an objective, quantitative, real-time reading of tumor information so that oncologists can provide optimum care for their patients¹.

Benefits of CellSearch™
The CellSearch™ CTC Test is a simple blood test that provides:

An independant predictor of survival:
CTCs are proven to be a strong, independent predictor of Overall Survival (OS) and Progression Free Survival (PFS)

Greater insight than standard tests alone:
As an adjunct to current standard testing methods, CTC assessment provides a more complete picture of patient prognosis

More informed decisions at any time:
Serial monitoring of CTCs can indicate a significant change in prognosis as early as after the first treatment cycle and at each step of the way

When to use the CellSearch™ CTC test:
Order the test prior to initiation of therapy to get CTC baseline, then order repeat tests at follow-up visits to assess prognosis and to inform patient care decisions.

1- The CellSearch™ CTC Test results should be used in conjunction with all clinical information derived from diagnostic tests (e.g. imaging or laboratory tests), physical examination, and complete medical history, in accordance with appropriate management procedures.
Reference: Instructions for Use, Veridex, LLC

Specimen Submission
Specimens may be sent via FedEx or our available courier services

Result Reports
It is the goal of our laboratory to report results of all tests within 3 business days of specimen receipt.
Results can be sent by either Fax, Email or Tele-Pathology (live consultant).

Contact
Spencer D. Green,
M.S., M.B.A.H.A.
Business Director
UCD Department of Pathology, SOM
12801 E. 17th Ave,
Mail Stop 8104
PO Box 6511, RC1-South rm. 5100
Aurora, CO 80045
303.724.3707 | fax 303.724.3712

email: info.pathology@UCDenver.edu

Please allow us the opportunity to serve you!

Welcome

Anatomic Pathology - CMOCO